Check out our latest study exploring the immune response to anti-PD-L1 antibody. Can we predict – before treatment begins – whether someone will mount an effective immune response to checkpoint inhibitors? Our team at ImmunoBrain, in collaboration with Uri Nevo’s group at Tel Aviv University, investigated a specific aspect of this question using an agent-based modelling (ABM) approach.

ImmunoBrain to participate in the ADIS Symposium (25- 26 June, Sankt Augustin – Germany) “Towards Earlier Diagnosis of Alzheimer’s Disease”. The ADIS JPND project is a collaborative effort to advance the early diagnosis of Alzheimer’s disease. As a Project Partner in this consortium, ImmunoBrain is focused on immune system profiling and how changes in immune cell activity can serve as biomarkers for disease detection.

The work of Professor Michal Schwartz, our Chief Scientific Officer and co-founder, has been featured in The Times in an article on anti-aging vaccines. This piece centers around Professor Schwartz’s recent publication in the Neuron special on ‘aging,’ which sheds light on the connection between immune system imbalance and inflammation as we age. The research highlights the potential of our innovative treatment approach, which aims to boost the capabilities of the peripheral immune system to revitalize brain function.

ImmunoBrain has successfully completed enrollment for IBC-01-01, our Phase 1b clinical study of IBC-Ab002. IBC-Ab002 is a novel antibody designed to enhance the immune system’s ability to treat Alzheimer’s disease. With enrollment now complete, our focus remains on gathering critical data from our ongoing study to advance the program toward its next phase.

We are excited to announce the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as our President and Chief Executive Officer. Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies. His leadership and drug development experience and expertise will be important drivers in the growth of ImmunoBrain as we progress our drug development efforts.

Excited to share a Genetic Engineering & Biotechnology News interview with our co-founder and CSO Prof. Michal Schwartz, and Medical Director Dr. Tommaso Croese, describing the complexity of #alzheimersdisease and how the novel therapeutic approach of ImmunoBrain Checkpoint may be key for treating this disease

Our co-founder and CSO, Professor Michal Schwartz, is on this month’s cover of Forbes in Hebrew, featuring the 50 most influential women in science and technology of 2023

We are excited to have James Mackay join our Board of Directors. His leadership and global drug development experience in biopharma will be significant and supportive in our growth

Happy to announce we dosed our first two patients in the Phase 1b First In Human clinical trial investigating ImmunoBrain’s lead program, IBC-Ab002 for patients with early Alzheimer’s disease.

For its 25th anniversary Nature Neuroscience set down for a conversation with Professor Schwartz, as a leader in her field and winner of the 2023 Israel Prize in Life Sciences.

Excited to share that our co-founder and CSO Prof. Michal Schwartz, our Medical Director Dr. Tommaso Croese, and their colleagues at the Weizmann Institute published a review on Science titled “Transforming the understanding of brain immunity,” showcasing much of the evidence behind our novel therapeutic approach

We are very happy and excited to share that ImmunoBrain Checkpoint’s co-founder and CSO, Professor Michal Schwartz, is this year’s recipient of the Israel Prize in Life Sciences. The Israel Prize is the most important and prestigious prize of the State of Israel

We are excited to see a new #Nature paper by Prof. David Holtzman research group, showing the critical role of the adaptive immune response in neurodegeneration. The authors show, using different immune interventions in mouse models of amyloid and tauopathy, how interactions between T cells and microglia can shape and control development of brain pathology. In this context, the authors tested anti-PD-1 administration as a therapeutic intervention and show decrease in tau-mediated neurodegeneration and brain pathology which was associated with increased recruitment of regulatory T cells to the brain. These findings are in line with our preclinical research, suggesting PD-1/PD-L1 immune checkpoint blockade as a therapeutic approach for neurodegenerative diseases.

Neuron dedicated an issue to the very important topic of brain-immune system relationships, and features a review article by Professor Michal Schwartz, who pioneered this field.

As featured in a new Nature publication, a shift in understanding of the role of immunity in brain function has been led by our co-founder and CSO, Prof. Michal Schwartz

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Michal Schwartz, ImmunoBrain’s Chief Scientific Officer and her colleagues at Weizmann Institute published a review article on Nature Immunology on the importance of immune cells for brain surveillance and protection

Another research group, Xing et al. publishes a paper substantiating ImmunoBrain’s results and mechanism of action in the most recent Brain, Behavior, and Immunity.

Michal Schwartz, ImmunoBrain’s Chief Scientific Officer, co-authored a paper in Cell Press Trends in Immunology looking into non-neuronal brain cells and the implications for #Alzheimersdisease therapy.

We are delighted to announce that we have been awarded a $1,000,000 grant from the Alzheimer’s Association® under the 2020 Part the Cloud-Bill Gates Partnership Grant Program.

Earlier this year ImmunoBrain’s Chief Scientific Officer, Prof. Michal Schwartz, co-authored and published a review paper in the Journal of Immunology giving an overview of her 20 years of research.